Search Results - Lanyan Fang

Increasing impact of quantitative methods and modeling in establishment of bioequivalence and characterization of drug delivery by Miyoung Yoon, Andrew Babiskin, Meng Hu, Fang Wu, Sam G. Raney, Lanyan Fang, Liang Zhao

Connect to this object online.

Use of physiologically‐based pharmacokinetic modeling to understand the effect of omeprazole administration on the pharmacokinetics of oral extended‐release nifedipine by Ming‐Liang Tan, Zongming Gao, Andrew Babiskin, Myong‐Jin Kim, Lanyan Fang, Lei Zhang, Liang Zhao

Connect to this object online.

Development and comparison of model‐integrated evidence approaches for bioequivalence studies with pharmacokinetic end points by Xiaomei Chen, Henrik B. Nyberg, Mark Donnelly, Liang Zhao, Lanyan Fang, Mats O. Karlsson, Andrew C. Hooker

Connect to this object online.

Evaluation of model‐integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods by Henrik Bjugård Nyberg, Xiaomei Chen, Mark Donnelly, Lanyan Fang, Liang Zhao, Mats O. Karlsson, Andrew C. Hooker

Connect to this object online.

Mechanistic modeling of drug products applied to the skin: A workshop summary report by Eleftheria Tsakalozou, Khondoker Alam, Priyanka Ghosh, Jessica Spires, Sebastian Polak, Lanyan Fang, Srinivasa Sammeta, Ping Zhao, Sumit Arora, Sam G. Raney

Connect to this object online.

Evaluation of model‐based bioequivalence approach for single sample pharmacokinetic studies by Coralie Tardivon, Florence Loingeville, Mark Donnelly, Kairui Feng, Wanjie Sun, Guoying Sun, Stella Grosser, Liang Zhao, Lanyan Fang, France Mentré, Julie Bertrand

Connect to this object online.

Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report by Abdullah Al Shoyaib, Arian Emami Riedmaier, Anita Kumar, Partha Roy, Neil John Parrott, Lanyan Fang, Nilufer Tampal, Yuching Yang, Rebeka Jereb, Liang Zhao, Fang Wu

Connect to this object online.

Quantitative methods and modeling to assess COVID‐19‐interrupted in vivo pharmacokinetic bioequivalence studies with two reference batches by Yuqing Gong, Kairui Feng, Peijue Zhang, Jieon Lee, Yuzhuo Pan, Zhen Zhang, Zhanglin Ni, Tao Bai, Miyoung Yoon, Bing Li, Carol Y. Kim, Lanyan Fang, Liang Zhao

Connect to this object online.

Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches: A workshop overview by Andrew Babiskin, Fang Wu, Youssef Mousa, Ming‐Liang Tan, Eleftheria Tsakalozou, Ross L. Walenga, Miyoung Yoon, Sam G. Raney, James E. Polli, Anna Schwendeman, Vishalakshi Krishnan, Lanyan Fang, Liang Zhao

Connect to this object online.

Regulatory utility of physiologically‐based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report by Fang Wu, Youssef Mousa, Kimberly Raines, Chris Bode, Yu Chung Tsang, Rodrigo Cristofoletti, Hongling Zhang, Tycho Heimbach, Lanyan Fang, Filippos Kesisoglou, Amitava Mitra, James Polli, Myong‐Jin Kim, Jianghong Fan, Banu S. Zolnik, Duxin Sun, Yi Zhang, Liang Zhao

Connect to this object online.

Establishing the suitability of model‐integrated evidence to demonstrate bioequivalence for long‐acting injectable and implantable drug products: Summary of workshop by Yuqing Gong, Peijue Zhang, Miyoung Yoon, Hao Zhu, Ameya Kohojkar, Andrew C. Hooker, Murray P. Ducharme, Jogarao Gobburu, Géraldine Cellière, Parmesh Gajjar, Bing V. Li, Raja Velagapudi, Yu Chung Tsang, Anna Schwendeman, James Polli, Lanyan Fang, Robert Lionberger, Liang Zhao

Connect to this object online.